Subscribe to our Newsletter
Today: 21.Oct.2017
Articles
Categories
Search - Contacts
Content
Newsfeeds
Search - Weblinks
Monday, 15 August 2016 19:47

U.S. Patent Issued for Valley Fever Detection Technology Developed by NAU and TGen Featured

NAU News

Valley Fever is an Infection Caused by a Microscopic Fungus that Lives in Desert Soils and Typically Enters the Body Through the Lungs

 

Valley Fever, a potentially deadly dust-borne fungal disease, should be easier to diagnose and treat thanks to a testing technology developed by Northern Arizona University and the Translational Genomics Research Institute, and now protected by a patent issued by the U.S. Patent and Trademark Office.

NAU and TGen have exclusively licensed this technology to DxNA LLC, a company based in St. George, Utah, which plans to make this Valley Fever Test commercially available to hospitals and clinics upon completion of FDA clinical trials and a subsequent FDA 510(k) submission for review and clearance later this year.

Valley Fever is endemic to Phoenix and Tucson, but also is spreading throughout the arid regions of North and South America. It is an infection caused by the microscopic fungus Coccidioides, a pathogen that lives in desert soils and typically enters the body through the lungs. An estimated 150,000 Americans are infected annually by Valley Fever, and as many as 500 die each year.

“Currently, there is no definitive test for Valley Fever. Our new rapid, 1-hour, genetic-based test will provide physicians and patients with a precise diagnosis, enabling prompt treatment and preventing this disease from becoming more serious,” said Paul Keim, director of TGen’s Pathogen Genomics Division, or TGen North, based in Flagstaff.

“For the past decade, TGen has worked to develop better tools and technology to address Valley Fever, and we think it is critical to be able to apply our cutting-edge science to problems in our own backyard,” said Keim, who also is the Cowden Endowed Chair of Microbiology at NAU, and director of NAU’s Center for Microbial Genetics and Genomics.

Valley Fever most commonly causes a progressive lung infection, but can also spread to other parts of the body, including the skin, bone, brain and the rest of the nervous system.

Nearly 60 percent of those infected by Valley Fever—including other vertebrates, and especially dogs—develop no significant symptoms. However, some patients develop highly debilitating symptoms, such as cough, fever and fatigue. These symptoms are similar to other respiratory diseases caused by bacteria or virus, and often lead to delayed diagnoses and inappropriate treatment. Very severe Valley Fever can require lifelong treatment with antifungal drugs, and even result in death.

This new genetic-based test can precisely identify both strains of Valley Fever: Coccidioides posadasii, found in Arizona, New Mexico, Texas and much of Latin America, and Coccidioides immitus, which is found in California, Washington and Baja Mexico.

Most infections occur in central and southern Arizona. Each year on average, there are an estimated 150,000 cases in Arizona, resulting in more than 1,700 hospitalizations at a cost of more than $86 million.

 

Last modified on Monday, 15 August 2016 19:59
Login to post comments
All content copyright © 2007-2017 by eNewsAZ & may not be republished or reproduced without written permission. All Rights Reserved.

Editor Lynne LaMaster

Phone:928.458.5119

Prescott, Arizona